Non-exclusive drug discount agreement for Teriparatide
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Teriparatid (ATC-Code nach WHO: H05AA02)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
60 / 100
Risk factors
No guaranteed purchase volumes; actual demand depends on prescriptions and pharmacy behavior.
The Open House procedure may be terminated if exclusive agreements are signed, ending existing non-exclusive agreements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jan 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Non-exclusive drug discount agreements for Teriparatide under Open House model.
- No guaranteed volumes or exclusivity; participation open to eligible pharmaceutical companies.
Show full summary
This is a non-exclusive drug discount agreement (Rabattvereinbarung) for Teriparatide (ATC H05AA02) under an Open House model, published by AOK PLUS. The agreement is open to all pharmaceutical companies meeting eligibility criteria. No exclusivity, no guaranteed volumes, and no individual negotiations. The contract ends 31.01.2028. The procurement is not subject to standard EU procurement rules; the notice is published for transparency.
Risks
No guaranteed purchase volumes; actual demand depends on prescriptions and pharmacy behavior.
The Open House procedure may be terminated if exclusive agreements are signed, ending existing non-exclusive agreements.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participation open to pharmaceutical manufacturers as defined in §4 Abs.18 AMG.
- Acceptance of the standard Rabattvereinbarung terms.
Administrative
- Submission via DTVP portal (with prior access request).
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Teriparatide
Non-exclusive Rabattvereinbarung for Teriparatide; open to all pharmaceutical companies; no guaranteed purchase volumes; agreement ends 31.01.2028.
Location
Duration
Category
Award Criteria
Deadline
Award details
Not applicable - Open House model with no competitive award criteria.
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Teriparatid (ATC-Code nach WHO: H05AA02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 19 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 686726-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
60 / 100
Risk factors
No guaranteed purchase volumes; actual demand depends on prescriptions and pharmacy behavior.
The Open House procedure may be terminated if exclusive agreements are signed, ending existing non-exclusive agreements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications